glp 1 weight loss injection The Latest on GLP-1s | Lexington Medical Center Blog GLP-1s | AgelessRx

In the absence of GLP-1RA-specific data, clinicians must rely on existing literature, expert clinical judgement, and a patient-centered approach regarding dietary supplementation while using a GLP-1RA

The incidence of documented symptomatic hypoglycemia was 69% at 26 weeks

Appendix Table 1

Also likely, she said, is that some of those who are new to GLP-1s under the Bridge program will experience what 10% or more of all GLP-1 users run into: nausea, vomiting, diarrhea and other gastrointestinal side effects that cause them to discontinue using the drug or taper their dose

10.5812/ijem.13612 Int J Endocrinol Metab

Research demonstrates that patients using semaglutide for weight management can achieve an average weight loss of 12-15% of their starting body weight over 68 weeks